1,770 results
Search Results
2. NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
- Subjects
NEC Corp. ,Cancer -- Care and treatment ,Tumor antigens ,Cancer vaccines ,Computer industry ,Microcomputer industry ,Computer industry ,Workflow software - Abstract
NEC is leveraging AI to develop personalized cancer vaccines targeting specific neoantigens. Their white paper outlines a workflow from design to administration, incorporating advanced ICT technologies for potential broader applications [...]
- Published
- 2024
3. Critics assail paper claiming harm from cancer vaccine.
- Author
-
Normile D
- Subjects
- Humans, Japan, Periodicals as Topic, Cancer Vaccines adverse effects, Papillomavirus Vaccines adverse effects, Vaccination statistics & numerical data
- Published
- 2016
- Full Text
- View/download PDF
4. NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
- Subjects
NEC Corp. ,Cancer vaccines ,Computer industry ,Microcomputer industry ,Computer industry ,Workflow software ,Business, general - Abstract
TOKYO, Apr 8, 2024 - (JCN Newswire) - NEC Corporation (TSE: 6701) has released a white paper, 'Towards the realization of AI drug development: Comprehensive process workflow for the commercial [...]
- Published
- 2024
5. NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
- Subjects
Tumor antigens ,Cancer vaccines ,Workflow software ,General interest - Abstract
New Delhi, April 9 -- Click here for details and downloads (registration is not required)URL:www.nec.com/en/global/solutions/ai-drug/publication/index.html NEC is committed to taking on the challenge of realizing new cancer treatments by aiming [...]
- Published
- 2024
6. Challenges in developing personalized neoantigen cancer vaccines.
- Author
-
Katsikis PD, Ishii KJ, and Schliehe C
- Subjects
- Humans, Antigens, Neoplasm, Immune System, Immunotherapy, Cancer Vaccines therapeutic use, Neoplasms
- Abstract
The recent success of cancer immunotherapies has highlighted the benefit of harnessing the immune system for cancer treatment. Vaccines have a long history of promoting immunity to pathogens and, consequently, vaccines targeting cancer neoantigens have been championed as a tool to direct and amplify immune responses against tumours while sparing healthy tissue. In recent years, extensive preclinical research and more than one hundred clinical trials have tested different strategies of neoantigen discovery and vaccine formulations. However, despite the enthusiasm for neoantigen vaccines, proof of unequivocal efficacy has remained beyond reach for the majority of clinical trials. In this Review, we focus on the key obstacles pertaining to vaccine design and tumour environment that remain to be overcome in order to unleash the true potential of neoantigen vaccines in cancer therapy., (© 2023. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
7. Nucleic acid-based vaccine for ovarian cancer cells; bench to bedside.
- Author
-
Al-Hawary SIS, Jasim SA, Hjazi A, Oghenemaro EF, Kaur I, Kumar A, Al-Ani AM, Alwaily ER, Redhee AH, and Mustafa YF
- Subjects
- Humans, Female, Nucleic Acid-Based Vaccines, Antigens, Neoplasm, Ovarian Neoplasms drug therapy, Cancer Vaccines therapeutic use
- Abstract
Ovarian cancer continues to be a difficult medical issue that affects millions of individuals worldwide. Important platforms for cancer immunotherapy include checkpoint inhibitors, chimeric antigen receptor T cells, bispecific antibodies, cancer vaccines, and other cell-based treatments. To avoid numerous infectious illnesses, conventional vaccinations based on synthetic peptides, recombinant subunit vaccines, and live attenuated and inactivated pathogens are frequently utilized. Vaccine manufacturing processes, however, are not entirely safe and carry a significant danger of contaminating living microorganisms. As a result, the creation of substitute vaccinations is required for both viral and noninfectious illnesses, including cancer. Recently, there has been testing of nucleic acid vaccines, or NAVs, as a cancer therapeutic. Tumor antigens (TAs) are genetically encoded by DNA and mRNA vaccines, which the host uses to trigger immune responses against ovarian cancer cells that exhibit the TAs. Despite being straightforward, safe, and easy to produce, NAVs are not currently thought to be an ideal replacement for peptide vaccines. Some obstacles to this strategy include selecting the appropriate therapeutic agents (TAs), inadequate immunogenicity, and the immunosuppressive characteristic of ovarian cancer. We focus on strategies that have been employed to increase NAVs' effectiveness in the fight against ovarian cancer in this review., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
8. A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine.
- Author
-
Chandarana C and Tiwari A
- Subjects
- Humans, Neoplasms therapy, Neoplasms drug therapy, Neoplasms immunology, Cancer Vaccines therapeutic use, Clinical Trials as Topic
- Abstract
Background: Cancer and infectious diseases are one of the greatest challenges of modern medicine. An unhealthy lifestyle, poor drug use, or drug misuse contribute to the rise in morbidity and mortality brought on by these illnesses. The inadequacies of the medications now being used to treat these disorders, along with the growing issue of drug resistance, have compelled researchers to look for novel compounds with therapeutic promise. The number of infections and diseases has significantly abated due to vaccine development and use over time, which is described in detail. Several novel vaccines can now be produced by manipulating Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA), Messenger Ribonucleic acid (mRNA), proteins, viral vector Recombinant, and other molecules due to advances in genetic engineering and our understanding of the immune defense., Objective: The main topic of discussion is cancer-based vaccinations, which were developed less than a decade ago but have already been used to treat a wide range of both life-threatening and deadly diseases. It contains clinical studies for cancer vaccines against kidney, liver, prostate, cervix, and certain RNA-based cancer vaccines against breast and bladder cancer., Results: Numerous studies using various DNA and RNA-based methods have been conducted on the basis of cancer, with 9-10 diseases related to DNA and 8-9 diseases associated with RNA. Some of these studies have been completed, while others have been eliminated due to a lack of research; further studies are ongoing regarding the same., Conclusion: This brief discussion of vaccines and their varieties with examples also discusses vaccine clinical trials in relation to cancer diseases in this DNA and RNA-based cancer vaccine that has had successful clinical trials like the cervical cancer drug VGX-3100, the kidney cancer drug Pembrolizumab, MGN-1601, the prostate cancer drug pTVG-HP with rhGM-CSF, the melanoma cancer drug proteasome siRNA, and the lung cancer drug FRAME-001., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF
9. White paper on microbial anti-cancer therapy and prevention
- Author
-
Ke Liu, Steve H. Thorne, Daniel A. Saltzman, Peter Tattersall, Grant McFadden, Liang Deng, Balveen Kaur, Laura Evgin, Steve Fiering, Richard G. Vile, Sheryl Ruppel, Herbert Kim Lyerly, Robert M. Hoffman, James L. Gulley, Robert Coffin, Matthew Giacalone, Claudia Gravekamp, Ariel E. Marciscano, Halle Huihong Zhang, Neil S. Forbes, Eddie Moradian, Shibin Zhou, and Hal Gunn
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Genetic Vectors ,Immunology ,Treatment outcome ,Drug Evaluation, Preclinical ,Cancer therapy ,Cancer Vaccines ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,White paper ,Neoplasms ,medicine ,Animals ,Humans ,Immunology and Allergy ,Combined Modality Therapy ,Viral therapy ,Intensive care medicine ,Oncolytic Virotherapy ,Pharmacology ,Immune Stimulation ,Bacteria ,business.industry ,Clinical Studies as Topic ,Neoplasms therapy ,Cancer ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Biological Therapy ,Treatment Outcome ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Viruses ,Molecular Medicine ,Genetic Engineering ,business ,Research Article - Abstract
In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting (‘Microbial Based Cancer Therapy’) at the US National Cancer Institute in the summer of 2017. Here, we define ‘Microbial Therapy’ to include both oncolytic viral therapy and bacterial anticancer therapy. Both of these fields exploit tumor-specific infectious microbes to treat cancer, have similar mechanisms of action, and are facing similar challenges to commercialization. We designed this paper to nucleate this growing field of microbial therapeutics and increase interactions between researchers in it and related fields. The authors of this paper include many primary researchers in this field. In this paper, we discuss the potential, status and opportunities for microbial therapy as well as strategies attempted to date and important questions that need to be addressed. The main areas that we think will have the greatest impact are immune stimulation, control of efficacy, control of delivery, and safety. There is much excitement about the potential of this field to treat currently intractable cancer. Much of the potential exists because these therapies utilize unique mechanisms of action, difficult to achieve with other biological or small molecule drugs. By better understanding and controlling these mechanisms, we will create new therapies that will become integral components of cancer care.
- Published
- 2018
10. Biobohemia Pushes Forward Antigenic Essence Technology in Released Paper
- Subjects
Antigens ,Cancer vaccines ,General interest ,News, opinion and commentary - Abstract
CAMBRIDGE: Biobohemia, Inc. has issued the following news release: Biobohemia's scientists share in a released paper ('Changing Landscape of Cancer Vaccines-Novel Proteomics Platform for New Antigen Compositions') the experience gained [...]
- Published
- 2022
11. Biobohemia Released Paper on the Discovery of the Antigenic Essence of Cancer Cells
- Subjects
Vaccination ,Cancer ,Cancer cells ,Cancer vaccines ,General interest ,News, opinion and commentary - Abstract
BOSTON: Biobohemia, Inc. has issued the following news release: Scientists announced today that they have discovered why they have not succeeded in developing a vaccine against cancer. Vaccination is a [...]
- Published
- 2021
12. Biobohemia Released Paper on the Discovery of the Antigenic Essence of Cancer Cells
- Subjects
Vaccination ,Cancer ,Cancer cells ,Cancer vaccines ,Business ,News, opinion and commentary - Abstract
BOSTON, March 17, 2021 /PRNewswire/ -- Scientists announced today that they have discovered why they have not succeeded in developing a vaccine against cancer. Vaccination is a powerful tool that [...]
- Published
- 2021
13. Biobohemia Released Paper on the Discovery of the Antigenic Essence of Cancer Cells
- Subjects
Vaccination ,Cancer ,Cancer vaccines ,Health - Abstract
2021 MAR 31 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Scientists announced that they have discovered why they have not succeeded in developing a vaccine [...]
- Published
- 2021
14. Bigger Capital and District 2 Capital Issue White Paper in Support of DCVax-L, a Second-Generation Autologous Dendritic Cell Vaccine
- Subjects
Immunotherapy ,Medical colleges ,Cancer -- Genetic aspects ,Dendritic cells ,Hedge funds ,Cancer vaccines ,Business ,News, opinion and commentary - Abstract
In-depth Analysis of Northwest Biotherapeutics' Cancer Vaccine by an Expert in Cellular and Molecular Medicine Trained at the Johns Hopkins School of Medicine and the Ludwig Center for Cancer Genetics [...]
- Published
- 2018
15. Incorporation of the Tat cell-penetrating peptide into nanofibers improves the respective antitumor immune response.
- Author
-
Mohammadi M, Dehghani P, Mohseninia A, Roozbehani M, Hemphill A, and Hesamizadeh K
- Subjects
- Adjuvants, Immunologic pharmacology, Animals, Bone Marrow Cells immunology, CD8-Positive T-Lymphocytes drug effects, Cancer Vaccines pharmacology, Cell-Penetrating Peptides chemistry, Dendritic Cells drug effects, Dendritic Cells immunology, Epitopes, T-Lymphocyte drug effects, Epitopes, T-Lymphocyte immunology, Humans, Immunity immunology, Interferon-gamma genetics, Lymphocytes, Tumor-Infiltrating drug effects, Lymphocytes, Tumor-Infiltrating immunology, Mice, Nanofibers chemistry, Neoplasms immunology, Neoplasms pathology, T-Lymphocytes, Cytotoxic drug effects, T-Lymphocytes, Cytotoxic immunology, Cancer Vaccines immunology, Cell-Penetrating Peptides pharmacology, Immunity drug effects, Neoplasms drug therapy
- Abstract
A major challenge for the development of anticancer vaccines is the induction of a safe and effective immune response, particularly mediated by CD8+ T lymphocytes, in an adjuvant-free manner. In this respect, we present a simple strategy to improve the specific CD8+ T cell responses using KFE8 nanofibers bearing a Class I (Kb)-restricted peptide epitope (called E. nanofibers) without the use of adjuvant. We demonstrate that incorporation of Tat, a cell-penetrating peptide (CPP) of the HIV transactivator protein, into E. nanofibers remarkably enhanced tumor-specific CD8+ T cell responses. E. nanofibers containing 12.5% Tat peptide (E.Tat
12.5 nanofiber) increased antigen cross-presentation by bone marrow-derived dendritic cells as compared with E. nanofibers, or E. nanofibers containing 25 or 50% the Tat peptide. Uptake of KFE8.Tat12.5 nanofibers by dendritic cells (DCs) was significantly increased compared with KFE8 nanofiber lacking Tat. Peritoneal and lymph node DCs of mice immunized with E.Tat12.5 nanofibers exhibited increased presentation of the H2kb-epitope (reminiscent for cross-presentation) compared with DCs obtained from E. nanofiber vaccinated mice. Tetrameric and intracellular cytokine staining revealed that vaccination with E.Tat12.5 triggered a robust and specific CD8+ T lymphocyte response, which was more pronounced than in mice vaccinated with E. nanofibers alone. Furthermore, E.Tat12.5 nanofibers were more potent than E. nanofiber to induce antitumor immune response and tumor-infiltrating IFN-γ CD8 T lymphocyte. In terms of cancer vaccine development, we propose that harnessing the nanofiber-based vaccine platform with incorporated Tat peptide could present a simple and promising strategy to induce highly effective antitumor immune response., (© 2020 Wiley Periodicals LLC.)- Published
- 2021
- Full Text
- View/download PDF
16. Prevention of COVID-19: Preventive Strategies for General Population, Healthcare Setting, and Various Professions.
- Author
-
Moossavi S, Fehr K, Maleki H, Seyedpour S, Keshavarz-Fathi M, Tabasi F, Heravi M, Sharifian R, Shafiei G, Badihian N, Kelishadi R, Nematollahi S, Almasi M, Popescu S, Keshavarz-Fathi M, and Rezaei N
- Subjects
- Delivery of Health Care, Humans, Immunotherapy, SARS-CoV-2, COVID-19, Cancer Vaccines
- Abstract
The disease 2019 (COVID-19) made a public health emergency in early 2020. Despite attempts for the development of therapeutic modalities, there is no effective treatment yet. Therefore, preventive measures in various settings could help reduce the burden of disease. In this chapter, the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19, non-pharmaceutical approaches at individual and population level, chemoprevention, immunoprevention, preventive measures in different healthcare settings and other professions, special considerations in high-risk groups, and the role of organizations to hamper the psychosocial effects will be discussed.
- Published
- 2021
- Full Text
- View/download PDF
17. IASLC issues statement paper on liquid biopsy for lung cancer
- Subjects
Cancer vaccines ,Non-small cell lung cancer ,Biological markers ,Pharmaceuticals and cosmetics industries ,Health ,Science and technology ,International Association for the Study of Lung Cancer - Abstract
2018 JUL 9 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Vaccine Week -- DENVER - The lungs can be a difficult organ to biopsy with a needle, [...]
- Published
- 2018
18. IASLC issues statement paper on liquid biopsy for lung cancer
- Subjects
Cancer vaccines ,Non-small cell lung cancer ,Biological markers ,Pharmaceuticals and cosmetics industries ,Health ,Science and technology ,International Association for the Study of Lung Cancer - Abstract
2018 JUL 2 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Vaccine Week -- DENVER - The lungs can be a difficult organ to biopsy with a needle, [...]
- Published
- 2018
19. Proteogenomic Platform for Identification of Tumor Specific Antigens.
- Author
-
Faktor J, Hernychová L, Vojtěšek B, and Hupp T
- Subjects
- Humans, Mutation, Neoplasms genetics, Neoplasms immunology, Precision Medicine, Proteogenomics, T-Lymphocytes immunology, Antigens, Neoplasm, Cancer Vaccines, Neoplasms therapy
- Abstract
Background: Although immune responses to “cancer neoantigens” have been known for decades, the first neoantigen vaccines emerged only very recently. Current developments in genomics and proteomics have enabled descriptions of tumor mutational landscapes, and the immunogenicity of corresponding neoantigens can now be predicted either in silico or in vitro. Cancer regression could be achieved via a combination of neoantigen vaccination and an appropriate immunology approach. Research in model organisms and the results of initial clinical trials of neoantigen vaccines have shown them to be effective., Purpose: We aim to emphasize the importance of neoantigen vaccines in personalized cancer treatment and describe their preparation. We summarize mutations leading to expression of an immunogenic antigen necessary for vaccine development. The processes leading to activation of T-cell anticancer immunity in a patient are briefly introduced. We especially focus on the identification of high confidence neoantigens by next-generation sequencing (NGS) and mass spectrometry (MS), which is key element in the process of designing neoantigen vaccines. Briefly, we describe a proteogenomic platform for confident identification of mutant peptides in biological material. We mention the possibility of neoantigen quantification in biological material using mass spectrometry such as SRM (selected reaction monitoring) and SWATH (sequential windowed acquisition of all theoretical fragment ion spectra). Successful clinical studies demonstrating the potential of neoantigen vaccination in personalized cancer treatment are summarized at the end of the paper. Key words: vaccination - mass spectrometry - neoplasms - organ-specific neoantigen This work was supported by the project MEYS - NPS I - LO1413. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Accepted: 9. 7. 2018.
- Published
- 2018
- Full Text
- View/download PDF
20. Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention
- Subjects
Vaccination ,Trade and professional associations ,Cancer -- Prevention -- Care and treatment ,Papillomavirus infections ,Cervical cancer ,Cancer vaccines ,Business ,Science and technology - Abstract
Paper is First in a Series Based on Presentations from Cervical Cancer Prevention Forum Hosted by SGO CHICAGO, Aug. 3 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) has published [...]
- Published
- 2009
21. Scientific Paper on Inovio Pharmaceuticals SynCon[TM] DNA Vaccines and Intradermal DNA Delivery Technology One of Most Cited Articles in the Journal Vaccine
- Subjects
DNA ,Cancer -- Care and treatment ,Cancer vaccines ,Pharmaceutical industry ,Business ,Business, international - Abstract
BLUE BELL, Pa. -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific [...]
- Published
- 2010
22. Adverse Events in Cancer Immunotherapy.
- Author
-
Abdel-Wahab N, Alshawa A, and Suarez-Almazor ME
- Subjects
- Animals, Humans, Immunotherapy methods, Molecular Targeted Therapy, Neoplasms immunology, Neoplasms metabolism, Neoplasms pathology, Patient Safety, Risk Assessment, Risk Factors, Treatment Outcome, Antineoplastic Agents adverse effects, Cancer Vaccines adverse effects, Immunotherapy adverse effects, Neoplasms therapy
- Abstract
Cancer immunotherapy has resulted in durable responses in patients with metastatic disease, unseen with traditional chemotherapy. Several therapies have been approved by the Food and Drug Administration for the treatment of various cancers, including: immune checkpoint inhibitors, cytokines - interleukin 2 (IL-2) and interferon alpha (IFN), and the cancer vaccine sipuleucel-T. These therapies upregulate the immune system to enhance antitumor responses. As a consequence, they can cause inflammatory and immune-related adverse events that can affect one or more organs, can be serious, and on occasion lifethreatening. The management of these adverse events is complex, and requires a multidisciplinary approach involving not only oncologists, but also other internal medicine specialists, to ensure prompt diagnosis and optimal management of these complications.
- Published
- 2017
- Full Text
- View/download PDF
23. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy.
- Author
-
Li T, Chen G, Lin L, Li B, Wang X, Chen Y, Huang W, Cai M, Xiao Z, Shuai X, and Zhu K
- Subjects
- Animals, Cell Line, Tumor, Mice, Nanoparticles chemistry, Mice, Inbred BALB C, Female, Dendritic Cells immunology, Dendritic Cells drug effects, Biomimetic Materials chemistry, Neoplasms therapy, Neoplasms immunology, Nanovaccines, Manganese Compounds chemistry, Cancer Vaccines immunology, Oxides chemistry, T-Lymphocytes immunology, T-Lymphocytes drug effects, Immunotherapy methods
- Abstract
The development of manganese oxide-based chemodynamic immunotherapy is emerging as a key strategy against solid tumors. However, the limited efficacy of nanoplatform in inducing efficient tumor therapeutic effects and creating the prominent antitumor immune responses remains a crucial issue. In this study, we construct a novel multifunctional biomimetic nanovaccine comprising manganese oxide-loaded poly(2-diisopropylaminoethyl methacrylate) (MP) nanoparticles and a coating layer of hybrid cell membrane (RHM) derived from manganese oxide-remodeled 4T1 cells and dendritic cells (DCs) (collectively called MP@RHM) for combination chemodynamic immunotherapy. Compared with the nanovaccines coated with the single cell membrane, the MP@RHM nanovaccine highly efficiently activates both DCs and T cells to boost tumor-specific T cell, owing to the synergistic effects of abundant damage-associated molecular patterns, Mn
2+ , and T cell-stimulating moieties. Upon peritumoral injection, the MP@RHM nanovaccine targets both the tumor site for focused chemodynamic therapy and the lymph nodes for robust tumor-specific T cell priming, thereby achieving highly efficient chemodynamic immunotherapy. Moreover, as a preventive cancer nanovaccine, MP@RHM generates strong immunological memory to inhibit postoperative tumor metastasis and recurrence. Our study findings highlight a promising approach to construct a multifunctional biomimetic nanovaccine for personalized chemodynamic immunotherapy against solid tumors., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
24. Exosome-based anticancer vaccines: From Bench to bedside.
- Author
-
Zhao G, Wang Y, Xing S, Jiang Y, Ding J, Cai Y, Ma P, Miao H, Fang Y, Jiang N, Cui D, Yu Y, Tang Q, Wang S, and Li N
- Subjects
- Humans, Animals, Exosomes immunology, Exosomes metabolism, Cancer Vaccines immunology, Cancer Vaccines therapeutic use, Neoplasms immunology, Neoplasms therapy, Immunotherapy methods
- Abstract
Exosomes, a subset of extracellular vesicles, are released by all active cells and play a crucial role in intercellular communications. Exosomes could facilitate the transfer of various biologically active molecules, such as DNA, non-coding RNAs, and proteins, from donor to recipient cells, thereby participating in diverse biological and pathological processes. Besides, exosomes possess unique characteristics, including non-toxicity, low-immunogenicity, and stability within biological systems, rendering them highly advantageous for cancer drug development. Meanwhile, accumulating evidence suggests that exosomes originating from tumor cells and immune cells possess distinct composition profiles that play a direct role in anticancer immunotherapy. Of note, exosomes can transport their contents to specific cells, thereby exerting an impact on the phenotype and immune-regulatory functions of targeted cells. Therapeutic cancer vaccines, an emerging therapeutics of immunotherapy, could enhance antitumor immune responses by delivering a large number of tumor antigens, thereby augmenting the immune response against tumor cells. Therefore, the therapeutic rationale of cancer vaccines and exosome-based immunotherapy are almost similar to some extent, but some challenges have hindered their application in the clinical setting. Here, in this review, we first summarized the biogenesis, structure, compositions, and biological functions of exosomes. Then we described the roles of exosomes in cancer biology, particularly in tumor immunity. We also comprehensively reviewed current exosome-based anticancer vaccine development and we divided them into three types. Finally, we give some insights into clinical translation and clinical trial progress of exosome-based anticancer vaccines for future direction., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Current Trends and Innovative Approaches in Cancer Immunotherapy.
- Author
-
Kim J, Maharjan R, and Park J
- Subjects
- Humans, Animals, Genetic Therapy methods, Genetic Therapy trends, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors pharmacology, Antibodies, Monoclonal therapeutic use, Nanotechnology methods, Cytokines metabolism, Cytokines immunology, Neoplasms therapy, Neoplasms immunology, Immunotherapy methods, Immunotherapy trends, Tumor Microenvironment immunology, Cancer Vaccines immunology, Cancer Vaccines therapeutic use, Cancer Vaccines administration & dosage
- Abstract
Immunotherapy is one of the most promising therapeutic approaches in the field of cancer treatment. As a tumor progresses, tumor cells employ an array of immune-regulatory mechanisms to suppress immune responses within the tumor microenvironment. Using our understanding of these mechanisms, cancer immunotherapy has been developed to enhance the immune system's effectiveness in treating cancer. Numerous cancer immunotherapies are currently in clinical use, yet many others are either in different stages of development or undergoing clinical studies. In this paper, we briefly discuss the features and current status of cancer immunotherapies. This includes the application of monoclonal antibodies, immune checkpoint inhibitors, adoptive cell therapy, cytokine therapy, cancer vaccines, and gene therapy, all of which have gained significant recognition in clinical practice. Additionally, we discuss limitations that may hinder successful clinical utilization and promising strategies, such as combining immunotherapy with nanotechnology., (© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
- Published
- 2024
- Full Text
- View/download PDF
26. Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity.
- Author
-
Bouma RG, Nijen Twilhaar MK, Brink HJ, Affandi AJ, Mesquita BS, Olesek K, van Dommelen JMA, Heukers R, de Haas AM, Kalay H, Ambrosini M, Metselaar JM, van Rooijen A, Storm G, Oliveira S, van Kooyk Y, and den Haan JMM
- Subjects
- Animals, Humans, Mice, Female, Antigens, Neoplasm immunology, Antigens, Neoplasm administration & dosage, Lymphocyte Activation drug effects, Liposomes, Cancer Vaccines administration & dosage, Cancer Vaccines immunology, Single-Domain Antibodies immunology, Single-Domain Antibodies administration & dosage, T-Lymphocytes immunology, Mice, Inbred C57BL, Antigen-Presenting Cells immunology
- Abstract
Cancer vaccines can be utilized in combination with checkpoint inhibitors to optimally stimulate the anti-tumor immune response. Uptake of vaccine antigen by antigen presenting cells (APCs) is a prerequisite for T cell priming, but often relies on non-specific mechanisms. Here, we have developed a novel vaccination strategy consisting of cancer antigen-containing liposomes conjugated with CD169- or DC-SIGN-specific nanobodies (single domain antibodies) to achieve specific uptake by APCs. Our studies demonstrate efficient nanobody liposome uptake by human and murine CD169
+ and DC-SIGN+ APCs in vitro and in vivo when compared to control liposomes or liposomes with natural ligands for CD169 and DC-SIGN. Uptake of CD169 nanobody liposomes resulted in increased T cell activation by human APCs and stimulated naive T cell priming in mouse models. In conclusion, while nanobody liposomes have previously been utilized to direct drugs to tumors, here we show that nanobody liposomes can be applied as vaccination strategy that can be extended to other receptors on APCs in order to elicit a potent immune response against tumor antigens., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
27. Novel HER2-based multi-epitope vaccine (HER2-MEV) against HER2-positive breast cancer: In silico design and validation.
- Author
-
Seadawy MG, Lotfy MM, Saeed AA, and Ageez AM
- Subjects
- Female, Humans, Computer Simulation, Molecular Docking Simulation, Receptor, ErbB-2 immunology, Receptor, ErbB-2 metabolism, T-Lymphocytes, Helper-Inducer immunology, Breast Neoplasms immunology, Breast Neoplasms therapy, Cancer Vaccines immunology, Epitopes, T-Lymphocyte immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
Breast cancer (BC) continues to be the malignancy with the highest diagnosis rate worldwide. Between 15 % and 30 % of BC patients show overexpressed human epidermal growth factor receptor 2 (HER2), which is linked to poor clinical results in terms of invasiveness and recurrence risk. Passive immunity-based therapeutic approaches for treating HER2-enriched BC, are not effective and significant problems need to be tackled. Constructing multi-epitope vaccines is favored over single-epitope vaccines due to its ability to induce immunity against a variety of antigenic targets which will improve the efficacy of the vaccine. The current study describes a multi-epitope vaccine from HER2 protein against HER2-positive BC using several immunoinformatic techniques to achieve a potent and durable immune response. Nine Cytotoxic T lymphocytes (CTL) and five Helper T lymphocytes (HTL) epitopes were predicted and validated from HER2 protein using in silico tools. The expressed protein of the designed vaccine is predicted to be highly thermostable with better solubility. The predicted vaccine 3D structure was validated by ProSA servers and by the ERRAT server. Molecular docking analysis revealed a high binding affinity and stability of the designed vaccine with MHCI and TLR-2, 4, 7, and 9 receptors. The analysis of the C-ImmSim server revealed that the novel vaccine construct had the ability to elicit robust anti-cancerous innate, humoral, and cell-mediated immune responses. The vaccine can be a suitable option for HER2-positive BC patients and other patients with HER2-positive cancers to evoke immune responses. However, in vitro and in vivo experiments are needed to assess its effectiveness and safety., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies.
- Author
-
Zhang J, Terreni M, Liu F, Sollogoub M, and Zhang Y
- Subjects
- Humans, Animals, G(M3) Ganglioside immunology, Cancer Vaccines immunology, Neoplasms immunology, Neoplasms therapy
- Abstract
Ganglioside GM3 is one of the most common membrane-bound glycosphingolipids. The over-expression of GM3 on tumor cells makes it defined as a tumor-associated carbohydrate antigen (TACA). The specific expression property in cancers, especially in melanoma, make it become an important target to develop anticancer vaccines or immunotherapies. However, in the manner akin to most TACAs, GM3 is an autoantigen facing with problems of low immunogenicity and easily inducing immunotolerance, which means itself only cannot elicit a powerful enough immune response to prevent or treat cancer. With a comparative understanding of the mechanisms that how immune system responses to the carbohydrate vaccines, this review summarizes the studies on the recent efforts to development GM3-based anticancer vaccines., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention
- Subjects
Cancer -- Care and treatment ,Cancer -- Prevention ,Papillomavirus infections ,Vaccination ,Habitat destruction ,Cancer vaccines ,Trade and professional associations ,Cervical cancer - Abstract
The Society of Gynecologic Oncologists (SGO) has published the first in a series of four papers on a variety of cervical cancer issues and topics that were the focus of [...]
- Published
- 2009
30. Paper reports late preclinical step validating novel melanoma vaccine
- Subjects
T cells ,Biotechnology industry ,Antigenic determinants ,Drugs ,Cancer -- Care and treatment ,Cancer vaccines ,Melanoma ,Peptides ,Health ,Science and technology - Abstract
Generex Biotechnology Corporation (GNBT) announced the publication of a milestone paper in the cancer research journal, Journal of Immunotherapy. This paper reports a late preclinical step in validating a novel [...]
- Published
- 2005
31. Paper reports late preclinical step validating novel melanoma vaccine
- Subjects
Generex Biotechnology Corp. ,T cells ,Biotechnology industry ,Antigenic determinants ,Drugs ,Cancer -- Care and treatment ,Cancer vaccines ,Melanoma ,Peptides ,Pharmaceutical industry ,Health - Abstract
Generex Biotechnology Corporation (GNBT) announced the publication of a milestone paper in the cancer research journal, Journal of Immunotherapy. This paper reports a late preclinical step in validating a novel [...]
- Published
- 2005
32. Paper reports late preclinical step validating novel melanoma vaccine
- Subjects
Generex Biotechnology Corp. ,Cancer -- Care and treatment ,Drugs ,Pharmaceutical industry ,Biotechnology industry ,Peptides ,Cancer vaccines ,T cells ,Antigenic determinants ,Melanoma - Abstract
Generex Biotechnology Corporation (GNBT) announced the publication of a milestone paper in the cancer research journal, Journal of Immunotherapy. This paper reports a late preclinical step in validating a novel [...]
- Published
- 2005
33. Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials.
- Author
-
Malla R, Srilatha M, Muppala V, Farran B, Chauhan VS, and Nagaraju GP
- Subjects
- Humans, Female, Animals, Clinical Trials as Topic, Drug Delivery Systems methods, Cancer Vaccines administration & dosage, Cancer Vaccines immunology, Antigens, Neoplasm immunology, Triple Negative Breast Neoplasms immunology, Triple Negative Breast Neoplasms therapy, Immunotherapy methods
- Abstract
Immunotherapy is gaining prominence as a promising strategy for treating triple-negative breast cancer (TNBC). Neoantigens (neoAgs) and cancer-testis antigens (CTAs) are tumor-specific targets originating from somatic mutations and epigenetic changes in cancer cells. These antigens hold great promise for personalized cancer vaccines, as supported by preclinical and early clinical evidence in TNBC. This review delves into the potential of neoAgs and CTAs as vaccine candidates, emphasizing diverse strategies and delivery approaches. It also highlights the current status of vaccination modalities undergoing clinical trials in TNBC therapy. A comprehensive understanding of neoAgs, CTAs, vaccination strategies, and innovative delivery methods is crucial for optimizing neoAg-based immunotherapies in clinical practice., Competing Interests: Declaration of competing interest The author declares that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
34. Polydopamine nanoparticles cross-linked hyaluronic acid photothermal hydrogel with cascading immunoinducible effects for in situ antitumor vaccination.
- Author
-
Fang Z, Yan Z, Li Z, Yan C, Jia S, Qiu X, Wang Q, Hou H, Wu Y, Du F, Gong A, and Zhang M
- Subjects
- Animals, Mice, Humans, Imiquimod chemistry, Imiquimod pharmacology, Dendritic Cells immunology, Vaccination, Cell Line, Tumor, Immunotherapy methods, Cross-Linking Reagents chemistry, Neoplasms immunology, Neoplasms therapy, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic drug effects, Hyaluronic Acid chemistry, Polymers chemistry, Cancer Vaccines chemistry, Cancer Vaccines immunology, Indoles chemistry, Indoles pharmacology, Hydrogels chemistry, Nanoparticles chemistry
- Abstract
Tumor vaccine, which can effectively prevent tumor recurrence and metastasis, is a promising tool in tumor immunotherapy. However, heterogeneity of tumors and the inability to achieve a cascade effect limit the therapeutic effects of most developing tumor vaccine. We have developed a cascading immunoinducible in-situ mannose-functionalized polydopamine loaded with imiquimod phenylboronic hyaluronic acid nanocomposite gel vaccine (M/P-PDA@IQ PHA) through a boronic ester-based reaction. This reaction utilizes mannose-functionalized polydopamine loaded with imiquimod (M/P-PDA@IQ NAs) as a cross-linking agent to react with phenylboronic-grafted hyaluronic acid. Under near-infrared light irradiation, the M/P-PDA@IQ PHA caused local hyperthermia to trigger immunogenic cell death of tumor cells and tumor-associated antigens (TAAs) releasing. Subsequently, the M/P-PDA@IQ NAs which were gradually released by the pH/ROS/GSH-triggered degradation of M/P-PDA@IQ PHA, could capture and deliver these TAAs to lymph nodes. Finally, the M/P-PDA@IQ NAs facilitated maturation and cross-presentation of dendritic cells, as well as activation of cytotoxic T lymphocytes. Overall, the M/P-PDA@IQ PHA could serve as a novel in situ vaccine to stimulate several key nodes including TAAs release and capture, targeting lymph nodes and enhanced dendritic cells uptake and maturation as well as T cells activation. This cascading immune activation strategy can effectively elicit antitumor immune response., Competing Interests: Declaration of competing interest The authors declared that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
35. Advances in traditional herbal formulation based nano-vaccine for cancer immunotherapy: Unraveling the enigma of complex tumor environment and multidrug resistance.
- Author
-
Saeed Y, Zhong R, and Sun Z
- Subjects
- Animals, Humans, Drug Resistance, Multiple, Drug Resistance, Neoplasm drug effects, Cancer Vaccines immunology, Immunotherapy methods, Nanovaccines, Neoplasms immunology, Neoplasms therapy, Neoplasms drug therapy, Tumor Microenvironment drug effects, Tumor Microenvironment immunology
- Abstract
Cancer is attributed to uncontrolled cell growth and is among the leading causes of death with no known effective treatment while complex tumor microenvironment (TME) and multidrug resistance (MDR) are major challenges for developing an effective therapeutic strategy. Advancement in cancer immunotherapy has been limited by the over-activation of the host immune response that ultimately affects healthy tissues or organs and leads to a feeble response of the patient's immune system against tumor cells. Besides, traditional herbal medicines (THM) have been well-known for their essential role in the treatment of cancer and are considered relatively safe due to their compatibility with the human body. Yet, poor solubility, low bio-availability, and lack of understanding about their pathophysiological mechanism halt their clinical application. Moreover, considering the complex TME and drug resistance, the most precarious and least discussed concerns for developing THM-based nano-vaccination, are identification of specific biomarkers for drug inhibitory protein and targeted delivery of bioactive ingredients of THM on the specific sites in tumor cells. The concept of THM-based nano-vaccination indicates immunomodulation of TME by THM-based bioactive adjuvants, exerting immunomodulatory effects, via targeted inhibition of key proteins involved in the metastasis of cancer. However, this concept is at its nascent stage and very few preclinical studies provided the evidence to support clinical translation. Therefore, we attempted to capsulize previously reported studies highlighting the role of THM-based nano-medicine in reducing the risk of MDR and combating complex tumor environments to provide a reference for future study design by discussing the challenges and opportunities for developing an effective and safe therapeutic strategy against cancer., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. Dendritic cell-derived exosome (DEX) therapy for digestive system cancers: Recent advances and future prospect.
- Author
-
Al-Hawary SIS, Almajidi YQ, Bansal P, Ahmad I, Kaur H, Hjazi A, Deorari M, Zwamel AH, Hamzah HF, and Mohammed BA
- Subjects
- Humans, Digestive System Neoplasms immunology, Digestive System Neoplasms therapy, Digestive System Neoplasms pathology, Animals, Immunotherapy methods, Exosomes immunology, Dendritic Cells immunology, Cancer Vaccines therapeutic use, Cancer Vaccines immunology
- Abstract
Tumor-mediated immunosuppression is a fundamental obstacle to the development of dendritic cell (DC)-based cancer vaccines, which despite their ability to stimulate host anti-tumor CD8 T cell immunity, have not been able to generate meaningful therapeutic responses. Exosomes are inactive membrane vesicles that are nanoscale in size and are produced by the endocytic pathway. They are essential for intercellular communication. Additionally, DC-derived exosomes (DEXs) contained MHC class I/II (MHCI/II), which is frequently complexed with antigens and co-stimulatory molecules and is therefore able to prime CD4 and CD8 T cells that are specific to particular antigens. Indeed, vaccines with DEXs have been shown to exhibit better anti-tumor efficacy in eradicating tumors compared to DC vaccines in pre-clinical models of digestive system tumors. Also, there is room for improvement in the tumor antigenic peptide (TAA) selection process. DCs release highly targeted exosomes when the right antigenic peptide is chosen, which could aid in the creation of DEX-based antitumor vaccines that elicit more targeted immune responses. Coupled with their resistance to tumor immunosuppression, DEXs-based cancer vaccines have been heralded as the superior alternative cell-free therapeutic vaccines over DC vaccines to treat digestive system tumors. In this review, current studies of DEXs cancer vaccines as well as potential future directions will be deliberated., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier GmbH. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Vaccimel immunization is associated with enhanced response to treatment with anti-PD-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study.
- Author
-
Mordoh J, Schwab E, Bravo AI, Aris M, and Barrio MM
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Adjuvants, Immunologic therapeutic use, Immune Checkpoint Inhibitors therapeutic use, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Cancer Vaccines immunology, Cancer Vaccines therapeutic use, Melanoma, Cutaneous Malignant immunology, Melanoma, Cutaneous Malignant therapy, Programmed Cell Death 1 Receptor antagonists & inhibitors, Programmed Cell Death 1 Receptor immunology, Skin Neoplasms immunology, Skin Neoplasms therapy
- Abstract
Cancer vaccines are gaining ground as immunotherapy options. We have previously demonstrated in cutaneous melanoma (CM) patients that adjuvant treatment with VACCIMEL, a mixture of four irradiated CM cell lines co-adjuvanted with BCG and GM-CSF, increases the cellular immune response to melanocyte differentiation antigens, cancer-testis antigens and neoantigens, with respect to basal levels. On the other hand, it is also known that treatment with anti-PD-1 monoclonal antibodies (MAbs), acting on pre-existing tumor-reactive lymphocytes, induces clinical responses in CM patients, albeit in a fraction of treated patients. A combination of both treatments would appear therefore desirable. In this paper, we describe CM patients who, having progressed even years after vaccination, were treated with anti-PD-1 MAbs. In 5/5 of such progressor patients, complete responses were obtained which lasted between 3 and 65+ months. Three of the patients remain disease-free and two recurred. One of the patients passed away after a recurrence of brain metastases. We suggest that clonally expanded reactive lymphocytes induced by VACCIMEL partially remain as memory cells, which may be recalled after tumor recurrence and may foster ulterior activity of anti-PD-1 MAbs., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Mordoh, Schwab, Bravo, Aris and Barrio.)
- Published
- 2024
- Full Text
- View/download PDF
38. Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.
- Author
-
Sheikhlary S, Lopez DH, Moghimi S, and Sun B
- Subjects
- Humans, Animals, Antigens, Neoplasm immunology, Neoplastic Stem Cells immunology, Cancer Vaccines immunology, Cancer Vaccines therapeutic use, Neoplasms immunology, Neoplasms therapy
- Abstract
Cancer remains one of the global leading causes of death and various vaccines have been developed over the years against it, including cell-based, nucleic acid-based, and viral-based cancer vaccines. Although many vaccines have been effective in in vivo and clinical studies and some have been FDA-approved, there are major limitations to overcome: (1) developing one universal vaccine for a specific cancer is difficult, as tumors with different antigens are different for different individuals, (2) the tumor antigens may be similar to the body's own antigens, and (3) there is the possibility of cancer recurrence. Therefore, developing personalized cancer vaccines with the ability to distinguish between the tumor and the body's antigens is indispensable. This paper provides a comprehensive review of different types of cancer vaccines and highlights important factors necessary for developing efficient cancer vaccines. Moreover, the application of other technologies in cancer therapy is discussed. Finally, several insights and conclusions are presented, such as the possibility of using cold plasma and cancer stem cells in developing future cancer vaccines, to tackle the major limitations in the cancer vaccine developmental process.
- Published
- 2024
- Full Text
- View/download PDF
39. Targeting the "tumor microenvironment": RNA-binding proteins in the spotlight in colorectal cancer therapy.
- Author
-
Zhang Y, Zhang Y, Song J, Cheng X, Zhou C, Huang S, Zhao W, Zong Z, and Yang L
- Subjects
- Humans, Tumor Microenvironment, RNA-Binding Proteins genetics, Extracellular Matrix, Cancer Vaccines, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics
- Abstract
Colorectal cancer (CRC) is the third most common cancer and has the second highest mortality rate among cancers. The development of CRC involves both genetic and epigenetic abnormalities, and recent research has focused on exploring the ex-transcriptome, particularly post-transcriptional modifications. RNA-binding proteins (RBPs) are emerging epigenetic regulators that play crucial roles in post-transcriptional events. Dysregulation of RBPs can result in aberrant expression of downstream target genes, thereby affecting the progression of colorectal tumors and the prognosis of patients. Recent studies have shown that RBPs can influence CRC pathogenesis and progression by regulating various components of the tumor microenvironment (TME). Although previous research on RBPs has primarily focused on their direct regulation of colorectal tumor development, their involvement in the remodeling of the TME has not been systematically reported. This review aims to highlight the significant role of RBPs in the intricate interactions within the CRC tumor microenvironment, including tumor immune microenvironment, inflammatory microenvironment, extracellular matrix, tumor vasculature, and CRC cancer stem cells. We also highlight several compounds under investigation for RBP-TME-based treatment of CRC, including small molecule inhibitors such as antisense oligonucleotides (ASOs), siRNAs, agonists, gene manipulation, and tumor vaccines. The insights gained from this review may lead to the development of RBP-based targeted novel therapeutic strategies aimed at modulating the TME, potentially inhibiting the progression and metastasis of CRC., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response
- Author
-
Yonghui Liu, Yujia Zhao, Xiaoshuang Wang, Xiaosu Chen, Jia Li, Yanan Chen, Jianying Lv, Yanhua Liu, Jie Shi, Xuan Qin, Yi Shi, Rong Xiang, and Siyu Li
- Subjects
Pam3CSK4 ,medicine.medical_treatment ,Medicine (miscellaneous) ,Cancer Vaccines ,Immune tolerance ,tumor immunotherapy ,PD1/PD-L1 ,Lipopeptides ,Mice ,Immune system ,Antigen ,Antigens, Neoplasm ,Cell Line, Tumor ,medicine ,Animals ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,Glycoproteins ,biology ,business.industry ,Immunogenicity ,Cancer ,Mammary Neoplasms, Experimental ,Immunotherapy ,glycoengineering ,medicine.disease ,tetra acetyl-N-azidoacetyl-mannosamine ,Cancer cell ,biology.protein ,Cancer research ,Female ,Antibody ,business ,Research Paper - Abstract
The lack of tumor specific antigens (TSA) and the immune tolerance are two major obstacles for the immunotherapy of cancer. Current immune checkpoint inhibitors (ICIs) show clinical responses in only limited subsets of cancer patients, which, to some extent, depends on the mutation load of tumor cells that may generate neoantigens. Here, we aimed to generate a neoantigen MDP to exhibit stronger anti-tumor efficacy. Methods: In this study, we utilized chemically modified sialic acid precursor tetra acetyl-N-azidoacetyl-mannosamine (AC4ManNAZ) to engineer the glycoproteins on the membranes of tumor cells for the covalent ligation of hapten adjuvant Pam3CSK4 in vivo, which eventually generated a neoantigen, i.e., ManNAZ-DBCO-Pam3CSK4 (MDP), on tumor cells. The high labeling efficiency, relatively specific biodistribution in tumor tissues and the anti-tumor efficacy were confirmed in the syngeneic murine models of the breast cancer and the lung cancer. Results: The generation of MDP neoantigen in tumor-bearing mice significantly evoked both the humoral and the T-cell-dependent antitumor immune responses, resulting in a strong inhibition on the growth of the breast cancer and the lung cancer allografts and significantly prolonged survival of tumor-bearing mice. Interestingly, MDP neoantigen was able to dramatically increase the sensitivity of cancer cells to ICIs and greatly enhance the anti-tumor efficacy in the murine models of both breast cancer and the lung cancer, which showed no or low responses to the immunotherapy with anti-PD1 antibody alone. Conclusions: We developed a simple metabolic glycoengineering method to artificially generate neoantigens on tumor cells to enhance tumor cell immunogenicity, which is able to significantly improve the response and the clinical outcome of ICIs.
- Published
- 2021
41. 90K predicts the prognosis of glioma patients and enhances tumor lysate-pulsed DC vaccine for immunotherapy of GBM in vitro
- Author
-
Xin Chen and Yu Zeng
- Subjects
Aging ,medicine.medical_treatment ,Malignancy ,Cancer Vaccines ,DC vaccine ,90K ,Antigens, Neoplasm ,Glioma ,medicine ,Biomarkers, Tumor ,Cytotoxic T cell ,LGALS3BP ,Humans ,business.industry ,Brain Neoplasms ,Cell Biology ,Immunotherapy ,Dendritic cell ,Dendritic Cells ,medicine.disease ,Prognosis ,CTL ,Apoptosis ,Cancer research ,Biomarker (medicine) ,business ,Research Paper - Abstract
Objectives: This study aimed to investigate the relationship between 90K expression with glioma malignancy and prognosis. Additionally, the enhancement effect of 90K in the Dendritic cell (DC) vaccine for Immunotherapy of glioblastoma (GBM) was evaluated in vitro. Methods: The expression of 90K protein in glioma tissues was detected by western blot. The relationship between the 90K expression and the tumor grade as well as the prognosis of patients was further analyzed by mining TCGA and CGGA database. The concentration of IL-12p70 and IL-10 was detected by ELISA. T lymphocyte proliferation and lethal effect of cytotoxic T cell (CTL) were detected by CCK-8. Results: The expression of 90K was significantly higher in glioma than normal tissue and increased with tumor grade (P< 0.05). Higher 90K expression was observed in IDH wildtype glioma than IDH mutant and predicted worse overall survival for glioma patients. The concentration of IL-12p70 and IFN-γ was the highest in the Apoptosis U251-90K-DC group, in which group the ability to kill U251 cells by CTL was also the strongest. Conclusion: 90K was a useful biomarker for glioma malignancy and patient prognosis. The appearance of 90K enhanced the effect of Apoptosis U251-DC vaccine for immunotherapy of GBM.
- Published
- 2021
42. Senescent cell-derived vaccines: A new concept towards an immune response against cancer and aging?
- Subjects
IMMUNE response ,AGING ,VACCINES ,BIOLOGICAL products ,CANCER vaccines - Abstract
A new review paper published in Aging explores the concept of using senescent cell-derived vaccines as a potential immune response against cancer and aging. The paper discusses the role of tumor-associated senescent cells in cancer progression and regression and highlights the potential use of senolytics, drugs that eliminate senescent cells, in cancer treatment. The researchers also propose the idea of designing an adaptive anti-aging vaccine. The paper provides valuable insights into the current knowledge in this field. [Extracted from the article]
- Published
- 2024
43. Neutrophil infiltration and whole-cell vaccine elicited by N-dihydrogalactochitosan combined with NIR phototherapy to enhance antitumor immune response and T cell immune memory
- Author
-
Shuhong Qi, Lisen Lu, Feifan Zhou, Mengli Xu, Yuzhou Chen, Lu Chen, Wei R. Chen, Xiang Yu, and Zhihong Zhang
- Subjects
0301 basic medicine ,Lung Neoplasms ,laser immunotherapy ,medicine.drug_class ,T cell ,medicine.medical_treatment ,T-Lymphocytes ,Medicine (miscellaneous) ,whole-cell vaccine ,Immunostimulant ,immune memory ,Cancer Vaccines ,Metastasis ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Immune system ,Adjuvants, Immunologic ,Immunity ,medicine ,Animals ,Neoplasm Metastasis ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,Melanoma ,business.industry ,Immunotherapy ,Phototherapy ,medicine.disease ,3. Good health ,Mice, Inbred C57BL ,030104 developmental biology ,medicine.anatomical_structure ,Neutrophil Infiltration ,030220 oncology & carcinogenesis ,Cancer research ,intravital imaging ,Female ,business ,Infiltration (medical) ,Immunologic Memory ,Research Paper - Abstract
Melanoma is one of the deadliest malignancies with a high risk of relapse and metastasis. Long-term, tumor-specific, and systemic immunity induced by local intervention is ideal for personalized cancer therapy. Laser immunotherapy (LIT), a combination of local irradiation of laser and local administration of an immunostimulant, was developed to achieve such an immunity. Although LIT showed promising efficacy on tumors, its immunological mechanism is still not understood, especially its spatio-temporal dynamics. Methods: In this study, we investigated LIT-induced immunological responses using a 980-nm laser and a novel immunostimulant, N-dihydrogalactochitosan (GC). Then we followed the functions of key immune cells spatially and temporally using intravital imaging and immunological assays. Results: Immediately after LIT, GC induced a rapid infiltration of neutrophils which ingested most GC in tumors. The cytokines released to the serum peaked at 12 h after LIT. Laser irradiations produced photothermal effects to ablate the tumor, release damage-associated molecular patterns, and generate whole-cell tumor vaccines. LIT-treated tumor-bearing mice efficiently resisted the rechallenged tumor and prevented lung metastasis. Intravital imaging of tumor at rechallenging sites in LIT-treated mice revealed that the infiltration of tumor-infiltrating lymphocytes (TILs) increased with highly active motility. Half of TILs with arrest and confined movements indicated that they had long-time interactions with tumor cells. Furthermore, LIT has synergistic effect with checkpoint blockade to improve antitumor efficacy. Conclusion: Our research revealed the important role of LIT-induced neutrophil infiltration on the in situ whole-cell vaccine-elicited antitumor immune response and long-term T cell immune memory.
- Published
- 2020
44. Modularly Programmable Nanoparticle Vaccine Based on Polyethyleneimine for Personalized Cancer Immunotherapy
- Author
-
Sejin Son, Kyung Soo Park, Jutaek Nam, and James J. Moon
- Subjects
General Chemical Engineering ,medicine.medical_treatment ,General Physics and Astronomy ,Medicine (miscellaneous) ,Nanoparticle ,02 engineering and technology ,macromolecular substances ,010402 general chemistry ,01 natural sciences ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Systemic circulation ,Antigen ,Cancer immunotherapy ,medicine ,General Materials Science ,lcsh:Science ,Full Paper ,Chemistry ,General Engineering ,technology, industry, and agriculture ,Cancer ,Immunotherapy ,Full Papers ,021001 nanoscience & nanotechnology ,medicine.disease ,0104 chemical sciences ,PEGylation ,Cancer research ,nanoparticles ,lcsh:Q ,immunotherapy ,0210 nano-technology ,CD8 ,cancer vaccines ,neoantigens - Abstract
Nanoparticles (NPs) can serve as a promising vaccine delivery platform for improving pharmacological property and codelivery of antigens and adjuvants. However, NP‐based vaccines are generally associated with complex synthesis and postmodification procedures, which pose technical and manufacturing challenges for tailor‐made vaccine production. Here, modularly programmed, polyethyleneimine (PEI)‐based NP vaccines are reported for simple production of personalized cancer vaccines. Briefly, PEI is conjugated with neoantigens by facile coupling chemistry, followed by electrostatic assembly with CpG adjuvants, leading to the self‐assembly of nontoxic, sub‐50 nm PEI NPs. Importantly, PEI NPs promote activation and antigen cross‐presentation of antigen‐presenting cells and cross‐priming of neoantigen‐specific CD8+ T cells. Surprisingly, after only a single intratumoral injection, PEI NPs with optimal PEGylation elicit as high as ≈30% neoantigen‐specific CD8+ T cell response in the systemic circulation and sustain elevated CD8+ T cell response over 3 weeks. PEI‐based nanovaccines exert potent antitumor efficacy against pre‐established local tumors as well as highly aggressive metastatic tumors. PEI engineering for modular incorporation of neoantigens and adjuvants offers a promising strategy for rapid and facile production of personalized cancer vaccines., Modularly programmed, polyethyleneimine (PEI)‐based nanoparticle (NP) vaccines are developed for simple production of personalized cancer vaccines. PEI‐antigen conjugates and CpG adjuvants are mixed form nontoxic, sub‐50 nm PEI NPs. PEI NPs elicit strong, long‐lasting neoantigen‐specific CD8+ T cell response with potent antitumor efficacy against local as well as metastatic tumors. PEI NPs offer a promising strategy for personalized cancer vaccination.
- Published
- 2021
45. Gas Plasma Technology Augments Ovalbumin Immunogenicity and OT‐II T Cell Activation Conferring Tumor Protection in Mice
- Author
-
Lea Miebach, Anke Schmidt, Sander Bekeschus, Mihaela Delcea, Barbara M. Bröker, Eric Freund, Ulrike Martens, Jan-Wilm Lackmann, Michael Lalk, Daniel Mrochen, Ramona Clemen, Bernhard H. Rauch, and Kristian Wende
- Subjects
Plasma Gases ,General Chemical Engineering ,T-Lymphocytes ,General Physics and Astronomy ,Medicine (miscellaneous) ,02 engineering and technology ,Lymphocyte Activation ,01 natural sciences ,Mice ,General Materials Science ,Melanoma ,chemistry.chemical_classification ,biology ,Full Paper ,Immunogenicity ,General Engineering ,ROS ,Full Papers ,vaccines ,021001 nanoscience & nanotechnology ,Cell biology ,medicine.anatomical_structure ,medicine.symptom ,0210 nano-technology ,Ovalbumin ,T cell ,Science ,Inflammation ,010402 general chemistry ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Cancer Vaccines ,In vivo ,oxPTM ,Cell Line, Tumor ,medicine ,Animals ,Reactive oxygen species ,kINPen ,medicine.disease ,0104 chemical sciences ,Mice, Inbred C57BL ,Disease Models, Animal ,Oxidative Stress ,chemistry ,biology.protein ,Reactive Oxygen Species ,Ex vivo - Abstract
Reactive oxygen species (ROS/RNS) are produced during inflammation and elicit protein modifications, but the immunological consequences are largely unknown. Gas plasma technology capable of generating an unmatched variety of ROS/RNS is deployed to mimic inflammation and study the significance of ROS/RNS modifications using the model protein chicken ovalbumin (Ova vs oxOva). Dynamic light scattering and circular dichroism spectroscopy reveal structural modifications in oxOva compared to Ova. T cells from Ova‐specific OT‐II but not from C57BL/6 or SKH‐1 wild type mice presents enhanced activation after Ova addition. OxOva exacerbates this activation when administered ex vivo or in vivo, along with an increased interferon‐gamma production, a known anti‐melanoma agent. OxOva vaccination of wild type mice followed by inoculation of syngeneic B16F10 Ova‐expressing melanoma cells shows enhanced T cell number and activation, decreased tumor burden, and elevated numbers of antigen‐presenting cells when compared to their Ova‐vaccinated counterparts. Analysis of oxOva using mass spectrometry identifies three hot spots regions rich in oxidative modifications that are associated with the increased T cell activation. Using Ova as a model protein, the findings suggest an immunomodulating role of multi‐ROS/RNS modifications that may spur novel research lines in inflammation research and for vaccination strategies in oncology., Successful vaccination requires increased immunogenicity of antigens. Cold physical plasmas produce reactive oxygen and nitrogen species capable of eliciting oxidative protein modifications. Oxidation of ovalbumin (Ova) shows enhanced T cell activation, elevated numbers of antigen‐presenting cells, and decreases tumor burden in vivo upon vaccination.
- Published
- 2021
46. Ag85B-ENO1 46-82 therapeutic vaccines enhance anti-tumor immunity by inducing CD8 + T cells and remodeling tumor microenvironment.
- Author
-
Liu F, Huang H, Yang X, Jiang S, Xu A, Yu Z, Li J, Yu M, Wang Y, and Wang B
- Subjects
- Animals, Mice, CD8-Positive T-Lymphocytes, Mice, Inbred C57BL, Tumor Necrosis Factor-alpha pharmacology, Tumor Microenvironment, Carcinoma, Lewis Lung, Cancer Vaccines, Lung Neoplasms
- Abstract
Lung cancer is the leading cause of cancer-related morbidity and mortality in China. However, the effect of traditional cancer treatment is limited. Herein, we designed a therapeutic cancer vaccine based on the tumor-associated antigen mENO1, which can prevent lung cancer growth in vivo, and explored the underlying mechanism of Ag85B-ENO1
46-82 therapy. Lewis lung carcinoma (LLC) tumor-bearing immunocompetent C57BL/6 mice that received Ag85B-ENO146-82 treatment showed antitumor effect. Further, we detected CD8+ T, CD4+ T in LLC-bearing C57BL/6 mice to understand the impact of Ag85B-ENO146-82 therapy on antitumor capacity. The Ag85B-ENO146-82 therapy induced intensive infiltration of CD4+ and CD8+ T cells in tumors, increased tumor-specific IFN-γ and TNF-α secretion by CD8+ T cells and promoted macrophage polarization toward M1 phenotype. Flow cytometric analysis revealed that CD8+ T effector memory (TEM) cells and central memory (TCM) cells were upregulated. qPCR and ELISA analysis showed that the expression of IFN-γ and TNF-α were upregulated, whereas of IL1β, IL6 and IL10 were downregulated. This study demonstrated that Ag85B-ENO146-82 vaccine augmented antitumor efficacy, which was CD8+ T cells dependent. Our findings paved the way for therapeutic tumor-associated antigen peptide vaccines to enhance anti-tumor immunotherapy for treatment of cancer., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF
47. TripHLApan: predicting HLA molecules binding peptides based on triple coding matrix and transfer learning.
- Author
-
Wang M, Lei C, Wang J, Li Y, and Li M
- Subjects
- Humans, Protein Binding, Peptides chemistry, HLA Antigens chemistry, Histocompatibility Antigens Class II chemistry, Histocompatibility Antigens Class I chemistry, Machine Learning, Cancer Vaccines
- Abstract
Human leukocyte antigen (HLA) recognizes foreign threats and triggers immune responses by presenting peptides to T cells. Computationally modeling the binding patterns between peptide and HLA is very important for the development of tumor vaccines. However, it is still a big challenge to accurately predict HLA molecules binding peptides. In this paper, we develop a new model TripHLApan for predicting HLA molecules binding peptides by integrating triple coding matrix, BiGRU + Attention models, and transfer learning strategy. We have found the main interaction site regions between HLA molecules and peptides, as well as the correlation between HLA encoding and binding motifs. Based on the discovery, we make the preprocessing and coding closer to the natural biological process. Besides, due to the input being based on multiple types of features and the attention module focused on the BiGRU hidden layer, TripHLApan has learned more sequence level binding information. The application of transfer learning strategies ensures the accuracy of prediction results under special lengths (peptides in length 8) and model scalability with the data explosion. Compared with the current optimal models, TripHLApan exhibits strong predictive performance in various prediction environments with different positive and negative sample ratios. In addition, we validate the superiority and scalability of TripHLApan's predictive performance using additional latest data sets, ablation experiments and binding reconstitution ability in the samples of a melanoma patient. The results show that TripHLApan is a powerful tool for predicting the binding of HLA-I and HLA-II molecular peptides for the synthesis of tumor vaccines. TripHLApan is publicly available at https://github.com/CSUBioGroup/TripHLApan.git., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
48. Nitrated T cell epitope linked vaccine targeting CD47 elicits antitumor immune responses and acts synergistically with vaccine targeting PDL1.
- Author
-
Deng D, Li G, Xia X, Xu S, Gao L, Zhang L, Yao W, Tian H, and Gao X
- Subjects
- Humans, CD47 Antigen, Epitopes, T-Lymphocyte, Immunotherapy methods, Nitrates, Phagocytosis, Tumor Microenvironment, Neoplasms, Cancer Vaccines immunology
- Abstract
Despite the clinical breakthrough made by immune checkpoint blockades (ICB) in cancer immunotherapy, immunosuppressed tumor microenvironment (TME) remains a major impediment in the efficacy of ICB immunotherapy. In this study, we constructed a Nitrated T cell epitope (NitraTh) linked vaccine targeting CD47, namely CD47-NitraTh. CD47-NitraTh could repress the progression of tumor by inducing tumor-specific immune response. Furthermore, combination vaccination with CD47-NitraTh and PDL1-NitraTh could reconstruct tumor associated macrophage, enhance macrophage-mediated phagocytosis for tumor cells, and promote the activation of tumor infiltrating T cells. Notably, by activating chemokine signaling pathway, NitraTh based vaccines reversed immunosuppressed TME, resulting in improved therapeutic outcome for tumor. With the advantage of reversing immunosuppressed TME, NitraTh based vaccine seems an optimal immunotherapy strategy for patients who are not sensitive to antibody based ICB., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
49. Metformin improved a heterologous prime-boost of dual-targeting cancer vaccines to inhibit tumor growth in a melanoma mouse model.
- Author
-
Guo Q, Wang L, Wuriqimuge, Dong L, Feng M, Bao X, Zhang K, Cai Z, Qu X, Zhang S, Wu J, Wu H, Wang C, Yu X, Kong W, and Zhang H
- Subjects
- Animals, Mice, CD8-Positive T-Lymphocytes, Disease Models, Animal, Tumor Microenvironment, Cancer Vaccines, Melanoma, Metformin, Diabetes Mellitus, Type 2, Vaccines, DNA
- Abstract
Therapeutic cancer vaccines, which induce anti-tumor immunity by targeting specific antigens, constitute a promising approach to cancer therapy. Our previous work proposed an optimized heterologous immunization strategy using cancer gene vaccines co-targeting MUC1 and survivin. Administration of a DNA vaccine three times within a week followed by a single recombinant MVA (rMVA) boost was able to efficiently induce anti-tumor immunity and inhibit tumor growth in tumor-bearing mouse models However, the complex immunosuppressive tumor microenvironment always limits infiltration by vaccine-induced T cells. Modifying the immunosuppressive microenvironment of tumors would be a breakthrough in enhancing the therapeutic effects of a cancer vaccine. Recent studies have reported that metformin, a type 2 diabetes drug, may ameliorate the tumor microenvironment, thereby enhancing anti-tumor immunity. Here, we tested whether the combinational therapeutic strategy of cancer vaccines administered with a heterologous prime-boost strategy with metformin enhanced anti-tumor effects in a melanoma mouse model. The results showed that metformin promoted the transition of M2-tumor-associated macrophages (M2-TAM) to M1-TAM, induced more tumor-infiltrating proliferative CD4 and CD8 T cells, and decreased exhausted T cells. This combinational treatment induced anti-tumor immunity from cancer vaccines, ameliorating the tumor microenvironment, showing improved tumor inhibition, and prolonging survival in tumor-bearing mice compared with either a cancer vaccine or metformin alone., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis.
- Author
-
Liu Y, Li S, Chen L, Lin L, Xu C, Qiu H, Li X, Cao H, and Liu K
- Subjects
- Humans, Tumor Microenvironment, Bibliometrics, Cluster Analysis, Cancer Vaccines therapeutic use, Neoplasms therapy
- Abstract
Background: Tumor vaccines have become crucial in cancer immunotherapy, but, only a limited number of phase III clinical trials have demonstrated clinical efficacy. The crux of this issue is the inability of tumor vaccines to effectively harmonize the tumor microenvironment with its intricate interplay. One factor that can hinder the effectiveness of vaccines is the natural immunosuppressive element present in the tumor microenvironment. This element can lead to low rates of T-cell response specific to antigens and the development of acquired resistance. Conversely, anticancer vaccines alter the tumor microenvironment in conflicting manners, inducing both immune activation and immunological evasion. Hence, comprehending the correlation between tumor vaccines and the tumor microenvironment would establish a foundation for forthcoming tumor treatment., Objective: Our review explores the realm of research pertaining to tumor vaccinations and the tumor microenvironment. Our objective is to investigate the correlation between tumor vaccines and the tumor microenvironment within this domain. We then focus our review on the dominant international paradigms in this research field and visually illustrates the historical progression and emergent patterns observed in the past., Methods: From January 1, 1999 to February 7, 2023, 1420 articles on the interplay between tumor vaccines and the tumor microenvironment were published, according to The Clarivate Web of Science (WOS) database used in our review. A bibliometric review was designed for this collection and consisted of an evaluation. The evaluation encompassed various discernible attributes, including the year of publication, the journals in which the articles were published, the authors involved, the affiliated institutions, the geographical locations of the institutions, the references cited, and the keywords employed., Results: Between the years 1999 and 2022, publications saw a significant increase, from 3 to 265 annually. With 72 papers published, Frontiers in Immunology had the most manuscripts published. The Cancer Research publication garnered the highest number of citations, amounting to 2874 citations. The United States exerts significant dominance in the subject, with the National Cancer Institute being recognized as a prominent institution in terms of both productivity and influence. Furthermore, Elizabeth M. Jaffee was recognized as the field's most prolific and influential author with 24 publications and 1,756 citations. The co-occurrence cluster analysis was conducted on the top 197 keywords, resulting in the identification of five distinct clusters. The most recent high-frequency keywords, namely immune therapy, dendritic cell, tumor microenvironment, cancer, and vaccine, signify the emerging frontiers in the interaction between tumor vaccines and the tumor microenvironment., Conclusion: Our review uncovers insights into contemporary trends, global patterns of collaboration, fundamental knowledge, research areas of high interest, and emerging frontiers in the field of TME-targeted vaccines., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Liu, Li, Chen, Lin, Xu, Qiu, Li, Cao and Liu.)
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.